 |
10 Products |  |
2 Diseases | | 10 Products |
|
8 Trials |  |
225 News |  |
| «123 |
- || CinnoRA (adalimumab biosimilar) / CinnaGen
Clinical, P1 data, PK/PD data, Journal: A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers. (Pubmed Central) - Nov 27, 2020
P1
The results clearly showed the pharmacokinetic similarity of the biosimilar adalimumab to the originator. CinnoRA® was safe and well-tolerated in healthy volunteers, with no significant differences in safety from the reference product.
- || favipiravir / Generic mfg.
Clinical, Clinical protocol, Journal: Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. (Pubmed Central) - Nov 6, 2020
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
- || CinnoVex (IFN-β-1a biosimilar) / CinnaGen
Clinical, Journal: An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. (Pubmed Central) - Nov 6, 2020
P2
The intervention group (Arms1) will be treated with lopinavir / ritonavir (Kaletra) + high dose Interferon-β 1a (Recigen) and the control group will be treated with lopinavir / ritonavir (Kaletra) + low dose Interferon-β 1a (Recigen) (the base therapeutic regimen)...The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- ||||| Reditux (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Combination therapy: Trained under dr reddy #goodtoseeyouagain @SeemaAliBhat1 updates on #cll abrutinib approved in front line but results in combination with rituximab came back faster than expected @OncLiveSOSS #ipc @SAStricklandMD @VUMChealth @OhioState (Twitter) - Oct 2, 2020
- [VIRTUAL] Types of pharmaceutical intervention in patients with Multiple sclerosis (MS): A fine line between immunosuppressive and risk of COVID-19 infection () - Sep 3, 2020 - Abstract #MSDC2020MSDC_1623;
Besides, exposure to fingolimod and Ocrelizumab were associated with an increased risk of an upper respiratory infection when compared to no exposure or other drug exposure.Conclusions By analyzing MS DMTs, we thought that IFN-β is associated with a lower risk of pneumonia due to its antiviral effect. Thus, Interferon Beta Drugs can provide a less experienced risk in confronting with COVID-19.
- |||||| PegaGen (pegfilgrastim biosimilar) / CinnaGen, Neulasta (pegfilgrastim) / Roche
New trial: Safety and Effectiveness Assessment of PeGagen (clinicaltrials.gov) - Jul 6, 2020
P, N=654, Completed, Sponsor: Cinnagen
- || COVAX-19 (GC004) / Flinders University, Vaxine, GeneCure Biotechnologies, Medytox, CinnaGen
New P1 trial: COVAX19: Monovalent Recombinant COVID19 Vaccine (clinicaltrials.gov) - Jun 30, 2020
P1, N=40, Recruiting, Sponsor: Vaxine Pty Ltd
- || lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. (Pubmed Central) - Jun 11, 2020
P2
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- || COVAX-19 (GC004) / Flinders University, Vaxine, GeneCure Biotechnologies, Medytox, CinnaGen
New P1 trial: Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (clinicaltrials.gov) - Jun 11, 2020
P1, N=32, Not yet recruiting, Sponsor: GeneCure Biotechnologies
- |||| Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm
Enrollment open: RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov) - May 27, 2020
P3, N=140, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Not yet recruiting --> Recruiting
- || Reditux (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, PK/PD data, Journal: Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. (Pubmed Central) - May 23, 2020
Not yet recruiting --> Recruiting DRL_RI and RMP had equivalent PKs, with comparable efficacy, PDs, safety, and immunogenicity.
- Reditux (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen
[VIRTUAL] R-CHOP CHEMOTHERAPY INCLUDING BIOSIMILAR RITUXIMAB (REDDITUX ®) FOR DE-NOVO DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: REAL LIFE SINGLE CENTER EXPERIENCE () - May 16, 2020 - Abstract #EHA2020EHA_2091;
Infusion reactions were observed in 20% of patients. Prospective randomized clinical trials are needed to determine the efficacy and safety profile of Redditux®.
- |||| Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm
Trial initiation date: RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov) - Apr 8, 2020
P3, N=140, Not yet recruiting, Sponsor: Dr. Reddy's Laboratories Limited
Prospective randomized clinical trials are needed to determine the efficacy and safety profile of Redditux®. Initiation date: Feb 2020 --> May 2020
- | Reditux (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen
Retrospective data, Journal: Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. (Pubmed Central) - Mar 17, 2020
In this single center, retrospective, observational study, we have compared patient outcomes such complete response (CR), partial response (PR), and overall response rate (ORR) in a cohort of 152 patients in an Indian hospital, who were treated either with innovator rituximab or Reditux, a biosimilar...The differences in the 3-year event-free survival and overall survival were not statistically significant. Biosimilar rituximab can suitably and safely replace the innovator rituximab for treatment of diffuse large B cell lymphoma.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J
Clinical, Journal: Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. (Pubmed Central) - Feb 23, 2020
Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients.
- |||||||| Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm
New P3 trial: RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov) - Feb 13, 2020
P3, N=140, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- || Epogen, Procrit (epoetin alfa) / Amgen
Clinical, Journal: Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. (Pubmed Central) - Jan 17, 2020
P3
CinnaPoietin® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639).
- | Reditux (rituximab biosimilar) / Dr. Reddy's, Abbott, EMD Serono, CinnaGen
Trial completion: Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 13, 2020
P1/2, N=276, Completed, Sponsor: Dr. Reddy's Laboratories Limited
The trial was registered in Clinicaltrials.gov (NCT03408639). Recruiting --> Completed
- || Avonex (recombinant IFN-?-1a) / Biogen, CinnoVex (IFN-?-1a biosimilar) / CinnaGen
Trial completion: Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) (clinicaltrials.gov) - Jan 9, 2020
P1, N=40, Completed, Sponsor: Cinnagen
Recruiting --> Completed Recruiting --> Completed
- || Reditux (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, mycophenolate mofetil / Generic mfg., azathioprine orodispersible / Generic mfg.
Do people use alternatives such as azathioprine mycophenolate mofetil, reditux, etc? (Twitter) - Dec 18, 2019
- |||||||||| Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm
New P3 trial: FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera (clinicaltrials.gov) - Jun 4, 2019
P3, N=284, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- | CinnoRA (adalimumab biosimilar) / CinnaGen, Humira (adalimumab) / AbbVie
Trial initiation date: A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects (clinicaltrials.gov) - Sep 19, 2018
P1, N=74, Completed, Sponsor: Cinnagen
Recruiting --> Completed Initiation date: Apr 2017 --> Oct 2016
- | Avonex (recombinant IFN-?-1a) / Biogen, CinnoVex (IFN-?-1a biosimilar) / CinnaGen
New P1 trial: Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) (clinicaltrials.gov) - Aug 3, 2018
P1, N=40, Recruiting, Sponsor: Cinnagen
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
Trial completion date, Trial primary completion date, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Feb 14, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Initiation date: Apr 2017 --> Oct 2016 Trial primary completion date: Feb 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Feb 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
Enrollment open, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 30, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Trial primary completion date: Feb 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Feb 2020 Not yet recruiting --> Recruiting
- | Eprex (epoetin alfa) / J&J, CinnaPoietin (epoetin beta biosimilar) / CinnaGen
New P3 trial, Head-to-Head: Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients (clinicaltrials.gov) - Jan 24, 2018
P3, N=156, Completed, Sponsor: Cinnagen
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
New P3 trial, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 5, 2018
P3, N=234, Not yet recruiting, Sponsor: Cinnagen
- | CinnoRA (adalimumab biosimilar) / CinnaGen, Humira (adalimumab) / AbbVie
New P1 trial: A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects (clinicaltrials.gov) - Sep 5, 2017
P1, N=74, Completed, Sponsor: Cinnagen
- | CinnoRA (adalimumab biosimilar) / CinnaGen, Humira (adalimumab) / Eisai, AbbVie
New P3 trial, Head-to-Head: Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA (clinicaltrials.gov) - Jun 1, 2017
P3, N=136, Completed, Sponsor: Cinnagen
- || Reditux (rituximab biosimilar) / Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2/3 trial, Adverse events: Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients (clinicaltrials.gov) - Dec 23, 2016
P2/3, N=76, Completed, Sponsor: Isfahan University of Medical Sciences
- Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open, Trial primary completion date: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jul 14, 2016
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2021 --> Mar 2021
- Reditux (rituximab biosimilar) - Dr. Reddy's, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R / Pharm, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jan 21, 2016
P2, N=40, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- ||||| Reditux (rituximab biosimilar) / Dr. Reddy's, Abbott, EMD Serono, CinnaGen
New P1/2 trial: Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Nov 20, 2014
P1/2, N=276, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited